STREAMEX CORP

Company Overview

Filings describe the business under BioSig Technologies (now consolidated with the May 28, 2025 Streamex acquisition), which markets the PURE EP™ platform — a patented real‑time intracardiac signal‑processing system used in electrophysiology labs — and has pivoted from hardware distribution toward R&D and software/AI modules to improve pulsed field ablation (PFA) specificity. The combined company is early‑commercial, R&D‑centric, IP‑heavy (multiple issued and pending patents) and currently pre‑revenue on the Streamex side; it holds U.S. 510(k) clearance for PURE EP but faces limited commercial traction, supplier dependencies, and significant liquidity pressure (working capital deficits and a short cash runway without new financing). Recent operating swings reflect workforce reductions, sharp cuts to R&D, aggressive cost control, and multiple equity financings/ATM activity; acquisition accounting and integration under a new CEO have materially increased non‑cash expenses in 2025.

Executive Compensation Practices

Because operations are cash‑constrained, the company has relied heavily on equity‑based pay — most notably a large $12.1M stock‑based compensation charge in a single quarter tied to the Streamex transaction — making stock awards, warrants and conversion features key components of total executive pay. Filings highlight that stock‑based expense is measured under Black‑Scholes and other valuation judgments (volatility, expected term, forfeiture rates) that materially affect reported G&A and can be managed by accounting assumptions; acquisition‑related grants and finder’s fees also inflate equity compensation in transaction periods. In the medical‑device context, long‑dated equity incentives are likely tied to regulatory milestones (FDA/QSR compliance, clinical endpoints), commercialization KPIs (installed base, conversions to paid systems) and strategic partnerships, so pay is aligned to uncertain clinical/regulatory outcomes and capital‑raising needs rather than stable revenue growth.

Insider Trading Considerations

Insider trading patterns here will often reflect financing mechanics more than pure sentiment: frequent ATM sales, private placements, warrant issuances and note conversions have increased insider and investor opportunity to sell (or be diluted), so insider sales can be driven by liquidity events rather than negative information about operations. Watch for timing around clinical readouts, FDA/CE milestones, NASDAQ compliance communications and acquisition integration updates — those are material non‑public events that typically trigger blackout windows or 10b5‑1 plan activity. Also monitor related‑party conversions, Series C preferred redemption triggers, and large stock‑based grants/warrant exercises, all of which can change insider ownership and the available float; an insider buy during acute cash stress would be a stronger bullish signal than routine participation in financing closings.